Hangzhou AGS MedTech Co. Ltd.

As of June 30, 2026, Hangzhou AGS MedTech Co. Ltd. carries a market capitalization of 4.19B, placing it among publicly traded companies globally. Its enterprise value stands at 2.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hangzhou AGS MedTech Co. Ltd.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Hangzhou AGS MedTech Co. Ltd. has 81.12M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Hangzhou AGS MedTech Co. Ltd. maintains a current ratio of 13.66, meaning it holds 13.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Hangzhou AGS MedTech Co. Ltd. recorded 29.62M in income tax expense.

As of the close on October 22, 2026, Hangzhou AGS MedTech Co. Ltd.'s stock has declined approximately 19.24% over the past 52 weeks. The 50-day moving average sits at 53.51, while the 200-day moving average is 56.55.

As of June 30, 2026, Hangzhou AGS MedTech Co. Ltd. holds 1.98B in cash and equivalents against 71.55M in total debt, resulting in a net debt position of -1.37B. Total book value stands at 2.55B, with working capital of 2.21B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Hangzhou AGS MedTech Co. Ltd. paid dividends of 1.04 per share.

Hangzhou AGS MedTech Co. Ltd.'s most recent stock split took place on June 21, 2024 with a 5:7 split ratio.